Cambridge Trust Co. lessened its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 36.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 807 shares of the financial services provider’s stock after selling 457 shares during the quarter. Cambridge Trust Co.’s holdings in iShares Biotechnology ETF were worth $106,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of IBB. Royal Bank of Canada grew its position in iShares Biotechnology ETF by 0.4% in the 3rd quarter. Royal Bank of Canada now owns 1,706,281 shares of the financial services provider’s stock valued at $199,568,000 after buying an additional 7,013 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of iShares Biotechnology ETF by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock valued at $204,332,000 after acquiring an additional 521,820 shares in the last quarter. Jane Street Group LLC increased its stake in shares of iShares Biotechnology ETF by 11.2% during the third quarter. Jane Street Group LLC now owns 951,555 shares of the financial services provider’s stock valued at $111,294,000 after acquiring an additional 95,541 shares during the period. Commerce Bank raised its holdings in iShares Biotechnology ETF by 38.0% during the third quarter. Commerce Bank now owns 689,006 shares of the financial services provider’s stock worth $80,586,000 after purchasing an additional 189,847 shares in the last quarter. Finally, Barclays PLC lifted its position in iShares Biotechnology ETF by 205.0% in the third quarter. Barclays PLC now owns 391,633 shares of the financial services provider’s stock worth $45,806,000 after purchasing an additional 263,247 shares during the period. Institutional investors own 58.02% of the company’s stock.
iShares Biotechnology ETF Stock Down 1.8 %
Shares of NASDAQ IBB opened at $124.50 on Friday. iShares Biotechnology ETF has a 1 year low of $104.29 and a 1 year high of $138.74. The stock has a fifty day moving average price of $131.94 and a two-hundred day moving average price of $128.93.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.